Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190344 | 0.99 | PKM (0.40) | PKMKDM4EALDH1A1BRD4SMN1; SMN2 | |
| SCHEMBL4201904 | 0.87 | PKM (0.56) | PKMALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL4202479 | 0.86 | PKM (0.57) | PKMALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL4189928 | 0.85 | PKM (0.49) | PKMKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4195571 | 0.83 | PKM (0.44) | PKMKDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4185954 | 0.82 | PKM (0.43) | PKMKDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4193422 | 0.81 | PKM (0.42) | PKMKDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL14344011 | 0.81 | PKM (0.42) | PKMKDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL14343990 | 0.80 | PKM (0.41) | PKMKDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4202494 | 0.79 | ATM (0.49) | PKMKDM4EALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-09-29 | — | — | US | claimed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | claimed |
| EP-2655350-B1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | claimed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | claimed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | claimed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | claimed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| WO-2012151440-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | claimed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | claimed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| US-10087169-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170369481-A1 | Bicyclic PKM2 Activators | AGIOS PHARMACEUTICALS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-09-29 | — | — | US | disclosed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2655350-B1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | disclosed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012151440-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087169-B2 | Bicyclic PKM2 activators | PDK2, PDK3, PDK1 | PKM 6/4885KDM4E 630/4885ALDH1A1 2044/4885 |
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | PKM 1855/4885KDM4E 3328/4885ALDH1A1 2744/4885 |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | PDK2, PDK1, PDK3 | PKM 5/4885KDM4E 700/4885ALDH1A1 1184/4885 |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | PDK1, PDK2, PCK1 | PKM 7/4885KDM4E 803/4885ALDH1A1 1936/4885 |
| US-20170369481-A1 | Bicyclic PKM2 Activators | PDK2, PDK3, PDK1 | PKM 6/4885KDM4E 630/4885ALDH1A1 2044/4885 |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | PCK1, PDK2, PFKP | PKM 9/4885KDM4E 1772/4885ALDH1A1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.